3.66

12.62% 0.41

After Hours: 3.68 0.02 +0.55%

Esperion Therapeutics Inc (ESPR)

Overview News Price History Option Chain Financials Why ESPR Down? Discussions Forecast Stock Split

Esperion Therapeutics Inc stock is traded at $3.66, with a volume of 10.90M. It is up +12.62% in the last 24 hours and up +83.00% over the past month. Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Previous Close:

$3.25

Open:

$3.32

24h Volume:

10.90M

Relative Volume:

2.63

Market Cap:

$721.15M

Revenue:

$116.33M

Net Income/Loss:

$-209.25M

P/E Ratio:

-1.2979

EPS:

-2.82

Net Cash Flow:

$-135.49M

1W Performance:

+44.09%

1M Performance:

+83.00%

6M Performance:

+62.67%

1Y Performance:

+137.66%

1-Day Range:

$3.31

$3.81

1-Week Range:

$2.52

$3.81

52-Week Range:

$1.345

$3.81

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Name

Esperion Therapeutics Inc

Sector

Healthcare (1194)

Industry

Drug Manufacturers - Specialty & Generic (88)

Phone

734-887-3903

Address

3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI

Employee

240

Twitter

@esperioninc

Next Earnings Date

2024-11-07

Latest SEC Filings

ESPR's Discussions on Twitter

Compare ESPR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ESPR Esperion Therapeutics Inc	3.66	721.15M	116.33M	-209.25M	-135.49M	-2.12
ZTS Zoetis Inc	175.32	79.10B	9.15B	2.43B	2.31B	5.32
HLN Haleon Plc Adr	9.69	43.81B	14.26B	1.55B	0	0.3383
TAK Takeda Pharmaceutical Co Adr	13.67	43.34B	30.27B	1.93B	3.45B	0.6044
TEVA Teva Pharmaceutical Industries Ltd Adr	17.80	20.17B	16.77B	-959.00M	1.37B	-0.85
VTRS Viatris Inc	13.04	15.56B	15.05B	-883.30M	1.89B	-0.74

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-20-24	Downgrade	BofA Securities	Neutral → Underperform
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral
Nov-20-23	Resumed	JP Morgan	Neutral
Aug-01-23	Upgrade	Northland Capital	Under Perform → Market Perform
Jun-15-23	Upgrade	BofA Securities	Underperform → Buy
Mar-16-23	Downgrade	BofA Securities	Neutral → Underperform
Mar-16-23	Downgrade	Northland Capital	Market Perform → Under Perform
Mar-07-23	Upgrade	Credit Suisse	Underperform → Neutral
Feb-27-23	Resumed	BofA Securities	Neutral
Feb-24-23	Upgrade	Jefferies	Hold → Buy
Feb-03-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Aug-03-22	Downgrade	Credit Suisse	Neutral → Underperform
May-05-22	Upgrade	JP Morgan	Underweight → Neutral
Mar-10-22	Initiated	H.C. Wainwright	Buy
Oct-19-21	Downgrade	Credit Suisse	Outperform → Neutral
Oct-14-21	Downgrade	Morgan Stanley	Equal-Weight → Underweight
May-05-21	Downgrade	Stifel	Buy → Hold
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-11-21	Initiated	Morgan Stanley	Equal-Weight
Feb-12-21	Downgrade	Jefferies	Buy → Hold
Feb-09-21	Downgrade	Goldman	Neutral → Sell
Jan-15-21	Downgrade	BofA Securities	Buy → Neutral
Nov-10-20	Upgrade	Credit Suisse	Neutral → Outperform
Sep-29-20	Resumed	JP Morgan	Underweight
Aug-11-20	Downgrade	Credit Suisse	Outperform → Neutral
Apr-01-20	Resumed	BofA/Merrill	Buy
Mar-17-20	Upgrade	Citigroup	Neutral → Buy
Feb-24-20	Downgrade	Northland Capital	Outperform → Market Perform
Feb-14-20	Downgrade	Citigroup	Buy → Neutral
Sep-16-19	Upgrade	Goldman	Sell → Neutral
May-29-19	Downgrade	Goldman	Neutral → Sell
May-06-19	Upgrade	BofA/Merrill	Underperform → Neutral
Apr-26-19	Upgrade	Goldman	Sell → Neutral
Mar-13-19	Upgrade	JP Morgan	Underweight → Neutral
Jan-07-19	Reiterated	Needham	Strong Buy
Dec-13-18	Initiated	Goldman	Sell
Oct-29-18	Upgrade	Northland Capital	Market Perform → Outperform
Oct-16-18	Initiated	BTIG Research	Buy
Aug-17-18	Upgrade	Citigroup	Neutral → Buy
Jul-11-18	Downgrade	Northland Capital	Outperform → Market Perform
May-03-18	Downgrade	JP Morgan	Neutral → Underweight
May-02-18	Downgrade	BofA/Merrill	Buy → Underperform

View All

Esperion Therapeutics Inc Stock (ESPR) Latest News

10:36 AM

ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada - MSN

10:36 AM

08:12 AM

Parkman Healthcare Partners LLC Has $1.49 Million Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

08:12 AM

Dec 03, 2024

Approval Sought in Japan for New Drug to Lower Cholesterol - Streetwise Reports

Dec 03, 2024

Esperion stock soars to 52-week high of $3.41 amid robust gains - Investing.com Nigeria

Dec 03, 2024

Dec 02, 2024

Esperion seeks Health Canada approval for cholesterol drugs - Investing.com Canada

Dec 02, 2024

Esperion stock soars to 52-week high of $3.41 amid robust gains By Investing.com - Investing.com South Africa

Dec 02, 2024

Esperion seeks Health Canada approval for cholesterol drugs By Investing.com - Investing.com UK

Dec 02, 2024

Esperion Announces New Drug Submissions in Canada for - GlobeNewswire

Dec 02, 2024

Esperion Seeks Canadian Approval for Two Novel Cholesterol-Lowering Drugs | ESPR Stock News - StockTitan

Dec 02, 2024

FY2025 EPS Estimate for Esperion Therapeutics Cut by Analyst - MarketBeat

Dec 02, 2024

Dec 01, 2024

Wasatch Advisors LP Purchases 6,483,070 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Dec 01, 2024

Nov 30, 2024

Esperion Therapeutics (NASDAQ:ESPR) Stock Price Up 8.7%What's Next? - MarketBeat

Nov 30, 2024

Nov 28, 2024

Connor Clark & Lunn Investment Management Ltd. Buys 295,378 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) - MarketBeat

Nov 28, 2024

Nov 27, 2024

Esperion Therapeutics (NASDAQ:ESPR) Receives Buy Rating from HC Wainwright - MarketBeat

Nov 27, 2024

Nov 26, 2024

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia - GlobeNewswire

Nov 26, 2024

Esperion's Cholesterol Drug Shows 25% LDL Reduction in Japan Trial, Advances to NDA | ESPR Stock News - StockTitan

Nov 26, 2024

Nov 21, 2024

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire

Nov 21, 2024

Esperion to Present at Piper Sandler Healthcare Conference, Showcases Cardiovascular Pipeline | ESPR Stock News - StockTitan

Nov 21, 2024

Esperion's chief commercial officer sells shares worth $426 By Investing.com - Investing.com South Africa

Nov 21, 2024

Nov 20, 2024

Esperion's chief commercial officer sells shares worth $426 - Investing.com

Nov 20, 2024

Nov 19, 2024

Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright - MarketBeat

Nov 19, 2024

Nov 18, 2024

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 - The Manila Times

Nov 18, 2024

Nov 15, 2024

Esperion Therapeutics (NASDAQ:ESPR) Rating Lowered to Hold at StockNews.com - MarketBeat

Nov 15, 2024

Nov 14, 2024

ESPR: 3 Growth Stocks Under $10 That Analysts Predict Will Skyrocket - StockNews.com

Nov 14, 2024

Two Seas Capital LP Acquires Significant Stake in Esperion Thera - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Nov 08, 2024

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan

Nov 08, 2024